Germany · Delayed Price · Currency is EUR Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of EUR 5.44 billion. The enterprise value is 4.02 billion.
| Market Cap | 5.44B |
| Enterprise Value | 4.02B |
Important Dates
The next estimated earnings date is Wednesday, February 25, 2026.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 130.91M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +19.29% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 100.55% |
| Float | 117.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.21 |
| P/TBV Ratio | 2.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.18 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.61 |
Financial Position
The company has a current ratio of 8.83, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.83 |
| Quick Ratio | 8.56 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.14 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -20.83% and return on invested capital (ROIC) is -15.79%.
| Return on Equity (ROE) | -20.83% |
| Return on Assets (ROA) | -15.07% |
| Return on Invested Capital (ROIC) | -15.79% |
| Return on Capital Employed (ROCE) | -27.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.35M |
| Employee Count | 414 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -58.40% |
| 50-Day Moving Average | 44.36 |
| 200-Day Moving Average | 29.56 |
| Relative Strength Index (RSI) | 42.39 |
| Average Volume (20 Days) | 130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -691.69M |
| Pretax Income | -560.13M |
| Net Income | -560.13M |
| EBITDA | -681.67M |
| EBIT | -691.69M |
| Earnings Per Share (EPS) | -4.13 |
Balance Sheet
The company has 1.46 billion in cash and 71.97 million in debt, giving a net cash position of 1.39 billion.
| Cash & Cash Equivalents | 1.46B |
| Total Debt | 71.97M |
| Net Cash | 1.39B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.47B |
| Book Value Per Share | 18.96 |
| Working Capital | 1.34B |
Cash Flow
In the last 12 months, operating cash flow was -462.07 million and capital expenditures -66.97 million, giving a free cash flow of -529.04 million.
| Operating Cash Flow | -462.07M |
| Capital Expenditures | -66.97M |
| Free Cash Flow | -529.04M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vaxcyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.29% |
| Shareholder Yield | -19.29% |
| Earnings Yield | -10.30% |
| FCF Yield | -9.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |